Sarepta Therapeutics, Inc. (SRPT) Given “Outperform” Rating at William Blair
William Blair reaffirmed their outperform rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research report sent to investors on Monday. William Blair also issued estimates for Sarepta Therapeutics’ Q4 2018 earnings at ($0.39) EPS.
Several other brokerages have also commented on SRPT. Leerink Swann reiterated an outperform rating and issued a $66.00 price target on shares of Sarepta Therapeutics in a research note on Saturday. Instinet restated a buy rating and set a $84.00 price objective on shares of Sarepta Therapeutics in a research report on Monday. J P Morgan Chase & Co restated a hold rating on shares of Sarepta Therapeutics in a research report on Monday, September 25th. Robert W. Baird restated an outperform rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a report on Monday. Finally, Credit Suisse Group restated an outperform rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a report on Monday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $62.79.
Sarepta Therapeutics (NASDAQ SRPT) opened at 49.55 on Monday. The firm’s market cap is $3.19 billion. The firm’s 50-day moving average is $42.14 and its 200-day moving average is $35.85. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $63.03.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.19) EPS. On average, equities analysts anticipate that Sarepta Therapeutics will post ($1.22) earnings per share for the current year.
In related news, Director Edward M. Md Kaye sold 10,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $410,000.00. Following the sale, the director now directly owns 62,471 shares in the company, valued at $2,561,311. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Shamim Ruff sold 12,138 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Following the completion of the sale, the senior vice president now owns 27,312 shares in the company, valued at $1,173,596.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,056 shares of company stock valued at $3,224,208. Company insiders own 9.60% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Prentiss Smith & Co. Inc. raised its position in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $127,000. PNC Financial Services Group Inc. boosted its position in shares of Sarepta Therapeutics by 150.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares in the last quarter. Finally, Edge Wealth Management LLC purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth $175,000. Hedge funds and other institutional investors own 65.41% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.